Hybio Pharmaceutical Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 1,226

Employees

  • Stock Symbol
  • 300199

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $3.42
  • (As of Friday Closing)

Hybio Pharmaceutical General Information

Description

Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Hybio Medicine Park, No.37, Keji C.2nd
  • Shenzhen HI-tech Industrial Park
  • Shenzhen, Guangdong 518057
  • China
+86 0755
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
SHE
Vertical(s)
Corporate Office
  • Hybio Medicine Park, No.37, Keji C.2nd
  • Shenzhen HI-tech Industrial Park
  • Shenzhen, Guangdong 518057
  • China
+86 0755

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hybio Pharmaceutical Stock Performance

As of 13-Nov-2026, Hybio Pharmaceutical’s stock price is $3.42. Its current market cap is $3.02B with 883M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.42 $3.46 $2.35 - $4.15 $3.02B 883M 45.8M $0.07

Hybio Pharmaceutical Financials Summary

As of 30-Sep-2026, Hybio Pharmaceutical has a trailing 12-month revenue of $221M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,416,768 2,517,311 1,797,057 1,928,115
Revenue 221,335 134,378 82,252 60,974
EBITDA 75,804 40,945 12,822 (33,261)
Net Income 58,302 5,085 (24,201) (72,634)
Total Assets 588,649 450,780 412,080 462,319
Total Debt 298,486 272,516 245,808 283,434
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hybio Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hybio Pharmaceutical‘s full profile, request access.

Request a free trial

Hybio Pharmaceutical Patents

Hybio Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026061282-A1 Method for pulverizing polypeptide drug Pending 18-Sep-2024
EP-4831195-A1 Synthetic method for tirzepatide Pending 20-Dec-2023
WO-2025130972-A1 Synthetic method for tirzepatide Inactive 20-Dec-2023
WO-2024001877-A1 Polypeptide drug solution preparation and method for preparing same Inactive 30-Jun-2022
EP-4775268-A2 Anti-coronavirus polypeptide as well as derivative and application thereof Pending 31-Dec-2021 C07K14/00
To view Hybio Pharmaceutical’s complete patent history, request access »

Hybio Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hybio Pharmaceutical Investments & Acquisitions (6)

Hybio Pharmaceutical’s most recent deal was a Corporate with Carbon Cloud Intelligent Peptide. The deal was made on 03-Jul-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Carbon Cloud Intelligent Peptide 03-Jul-2025 Corporate Discovery Tools (Healthcare)
Dali Hanyu Biotechnology 17-Apr-2020 Corporate Pharmaceuticals
General Healthy 12-Oct-2015 Early Stage VC Enterprise Systems (Healthcare)
General Healthy 12-Oct-2015 Secondary Transaction - Private Enterprise Systems (Healthcare)
Prediktor 13-Feb-2015 Corporate Systems and Information Management
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Hybio Pharmaceutical ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

45.11 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Hybio Pharmaceutical’s complete esg history, request access »

Hybio Pharmaceutical Exits (4)

Hybio Pharmaceutical’s most recent exit was on 12-Oct-2015 from General Healthy. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
General Healthy 12-Oct-2015 Completed
  • 2 buyers
General Healthy 12-Oct-2015 Completed
  • 2 buyers
Prediktor 13-Feb-2015 Completed
ChanGee 19-Aug-2014 Merger/Acquisition Completed
To view Hybio Pharmaceutical’s complete exits history, request access »

Hybio Pharmaceutical Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
ChanGee Tianshui, China 2005

Hybio Pharmaceutical FAQs

  • When was Hybio Pharmaceutical founded?

    Hybio Pharmaceutical was founded in 1998.

  • Where is Hybio Pharmaceutical headquartered?

    Hybio Pharmaceutical is headquartered in Shenzhen, China.

  • What is the size of Hybio Pharmaceutical?

    Hybio Pharmaceutical has 1,226 total employees.

  • What industry is Hybio Pharmaceutical in?

    Hybio Pharmaceutical’s primary industry is Biotechnology.

  • Is Hybio Pharmaceutical a private or public company?

    Hybio Pharmaceutical is a Public company.

  • What is Hybio Pharmaceutical’s stock symbol?

    The ticker symbol for Hybio Pharmaceutical is 300199.

  • What is the current stock price of Hybio Pharmaceutical?

    As of 13-Nov-2026 the stock price of Hybio Pharmaceutical is $3.42.

  • What is the current market cap of Hybio Pharmaceutical?

    The current market capitalization of Hybio Pharmaceutical is $3.02B.

  • What is Hybio Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Hybio Pharmaceutical is $221M.

  • What is Hybio Pharmaceutical’s annual earnings per share (EPS)?

    Hybio Pharmaceutical’s EPS for 12 months was $0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process